Global Multiple Sclerosis (MS) Drugs Market Growth 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Multiple Sclerosis (MS) Drugs Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Multiple Sclerosis (MS) Drugs by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Multiple Sclerosis (MS) Drugs by Country/Region, 2017, 2022 & 2028

2.2 Multiple Sclerosis (MS) Drugs Segment by Type

2.2.1 Copaxone (Glatiramer Acetate, Copolymer 1)

2.2.2 Novantrone (Mitoxantrone)

2.2.3 Gilenya (Fingolimod, Fty720)

2.2.4 Aubagio (Teriflunomide)

2.2.5 Tecfidera (Dimethyl Fumarate)

2.2.6 Firategrast (Sb683699, T-0047)

2.2.7 Siponimod (Baf312)

2.2.8 Others

2.3 Multiple Sclerosis (MS) Drugs Sales by Type

2.3.1 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2017-2022)

2.3.2 Global Multiple Sclerosis (MS) Drugs Revenue and Market Share by Type (2017-2022)

2.3.3 Global Multiple Sclerosis (MS) Drugs Sale Price by Type (2017-2022)

2.4 Multiple Sclerosis (MS) Drugs Segment by Application

2.4.1 RRMS

2.4.2 SPMS

2.4.3 PPMS

2.4.4 PRMS

2.5 Multiple Sclerosis (MS) Drugs Sales by Application

2.5.1 Global Multiple Sclerosis (MS) Drugs Sale Market Share by Application (2017-2022)

2.5.2 Global Multiple Sclerosis (MS) Drugs Revenue and Market Share by Application (2017-2022)

2.5.3 Global Multiple Sclerosis (MS) Drugs Sale Price by Application (2017-2022)

3 Global Multiple Sclerosis (MS) Drugs by Company

3.1 Global Multiple Sclerosis (MS) Drugs Breakdown Data by Company

3.1.1 Global Multiple Sclerosis (MS) Drugs Annual Sales by Company (2020-2022)

3.1.2 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Company (2020-2022)

3.2 Global Multiple Sclerosis (MS) Drugs Annual Revenue by Company (2020-2022)

3.2.1 Global Multiple Sclerosis (MS) Drugs Revenue by Company (2020-2022)

3.2.2 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Company (2020-2022)

3.3 Global Multiple Sclerosis (MS) Drugs Sale Price by Company

3.4 Key Manufacturers Multiple Sclerosis (MS) Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Multiple Sclerosis (MS) Drugs Product Location Distribution

3.4.2 Players Multiple Sclerosis (MS) Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Multiple Sclerosis (MS) Drugs by Geographic Region

4.1 World Historic Multiple Sclerosis (MS) Drugs Market Size by Geographic Region (2017-2022)

4.1.1 Global Multiple Sclerosis (MS) Drugs Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Multiple Sclerosis (MS) Drugs Annual Revenue by Geographic Region

4.2 World Historic Multiple Sclerosis (MS) Drugs Market Size by Country/Region (2017-2022)

4.2.1 Global Multiple Sclerosis (MS) Drugs Annual Sales by Country/Region (2017-2022)

4.2.2 Global Multiple Sclerosis (MS) Drugs Annual Revenue by Country/Region

4.3 Americas Multiple Sclerosis (MS) Drugs Sales Growth

4.4 APAC Multiple Sclerosis (MS) Drugs Sales Growth

4.5 Europe Multiple Sclerosis (MS) Drugs Sales Growth

4.6 Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Growth

5 Americas

5.1 Americas Multiple Sclerosis (MS) Drugs Sales by Country

5.1.1 Americas Multiple Sclerosis (MS) Drugs Sales by Country (2017-2022)

5.1.2 Americas Multiple Sclerosis (MS) Drugs Revenue by Country (2017-2022)

5.2 Americas Multiple Sclerosis (MS) Drugs Sales by Type

5.3 Americas Multiple Sclerosis (MS) Drugs Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Multiple Sclerosis (MS) Drugs Sales by Region

6.1.1 APAC Multiple Sclerosis (MS) Drugs Sales by Region (2017-2022)

6.1.2 APAC Multiple Sclerosis (MS) Drugs Revenue by Region (2017-2022)

6.2 APAC Multiple Sclerosis (MS) Drugs Sales by Type

6.3 APAC Multiple Sclerosis (MS) Drugs Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 Europe

7.1 Europe Multiple Sclerosis (MS) Drugs by Country

7.1.1 Europe Multiple Sclerosis (MS) Drugs Sales by Country (2017-2022)

7.1.2 Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2017-2022)

7.2 Europe Multiple Sclerosis (MS) Drugs Sales by Type

7.3 Europe Multiple Sclerosis (MS) Drugs Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Multiple Sclerosis (MS) Drugs by Country

8.1.1 Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Country (2017-2022)

8.1.2 Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue by Country (2017-2022)

8.2 Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Type

8.3 Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Multiple Sclerosis (MS) Drugs

10.3 Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs

10.4 Industry Chain Structure of Multiple Sclerosis (MS) Drugs

11 Marketing, Distributors and Customer

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Multiple Sclerosis (MS) Drugs Distributors

11.3 Multiple Sclerosis (MS) Drugs Customer

12 World Forecast Review for Multiple Sclerosis (MS) Drugs by Geographic Region

12.1 Global Multiple Sclerosis (MS) Drugs Market Size Forecast by Region

12.1.1 Global Multiple Sclerosis (MS) Drugs Forecast by Region (2023-2028)

12.1.2 Global Multiple Sclerosis (MS) Drugs Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Multiple Sclerosis (MS) Drugs Forecast by Type

12.7 Global Multiple Sclerosis (MS) Drugs Forecast by Application

13 Key Players Analysis

13.1 Bayer AG

13.1.1 Bayer AG Company Information

13.1.2 Bayer AG Multiple Sclerosis (MS) Drugs Product Offered

13.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 Bayer AG Main Business Overview

13.1.5 Bayer AG Latest Developments

13.2 Bayhill Therapeutics

13.2.1 Bayhill Therapeutics Company Information

13.2.2 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Offered

13.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 Bayhill Therapeutics Main Business Overview

13.2.5 Bayhill Therapeutics Latest Developments

13.3 Biogen Idec

13.3.1 Biogen Idec Company Information

13.3.2 Biogen Idec Multiple Sclerosis (MS) Drugs Product Offered

13.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Biogen Idec Main Business Overview

13.3.5 Biogen Idec Latest Developments

13.4 Cinnagen

13.4.1 Cinnagen Company Information

13.4.2 Cinnagen Multiple Sclerosis (MS) Drugs Product Offered

13.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 Cinnagen Main Business Overview

13.4.5 Cinnagen Latest Developments

13.5 Daiichi Sankyo

13.5.1 Daiichi Sankyo Company Information

13.5.2 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Offered

13.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 Daiichi Sankyo Main Business Overview

13.5.5 Daiichi Sankyo Latest Developments

13.6 Eli Lilly

13.6.1 Eli Lilly Company Information

13.6.2 Eli Lilly Multiple Sclerosis (MS) Drugs Product Offered

13.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 Eli Lilly Main Business Overview

13.6.5 Eli Lilly Latest Developments

13.7 Fast Forward Llc

13.7.1 Fast Forward Llc Company Information

13.7.2 Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Offered

13.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 Fast Forward Llc Main Business Overview

13.7.5 Fast Forward Llc Latest Developments

13.8 Antisense Therapeutics

13.8.1 Antisense Therapeutics Company Information

13.8.2 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Offered

13.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 Antisense Therapeutics Main Business Overview

13.8.5 Antisense Therapeutics Latest Developments

13.9 Apitope

13.9.1 Apitope Company Information

13.9.2 Apitope Multiple Sclerosis (MS) Drugs Product Offered

13.9.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 Apitope Main Business Overview

13.9.5 Apitope Latest Developments

13.10 Five Prime Therapeutics

13.10.1 Five Prime Therapeutics Company Information

13.10.2 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Offered

13.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 Five Prime Therapeutics Main Business Overview

13.10.5 Five Prime Therapeutics Latest Developments

13.11 Genmab

13.11.1 Genmab Company Information

13.11.2 Genmab Multiple Sclerosis (MS) Drugs Product Offered

13.11.3 Genmab Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 Genmab Main Business Overview

13.11.5 Genmab Latest Developments

13.12 Artielle Immunotherapeutics

13.12.1 Artielle Immunotherapeutics Company Information

13.12.2 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Offered

13.12.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.12.4 Artielle Immunotherapeutics Main Business Overview

13.12.5 Artielle Immunotherapeutics Latest Developments

13.13 Genzyme

13.13.1 Genzyme Company Information

13.13.2 Genzyme Multiple Sclerosis (MS) Drugs Product Offered

13.13.3 Genzyme Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.13.4 Genzyme Main Business Overview

13.13.5 Genzyme Latest Developments

13.14 Glaxosmithkline

13.14.1 Glaxosmithkline Company Information

13.14.2 Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Offered

13.14.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.14.4 Glaxosmithkline Main Business Overview

13.14.5 Glaxosmithkline Latest Developments

13.15 Gw Pharmaceuticals

13.15.1 Gw Pharmaceuticals Company Information

13.15.2 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Offered

13.15.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.15.4 Gw Pharmaceuticals Main Business Overview

13.15.5 Gw Pharmaceuticals Latest Developments

13.16 Innate Immunotherapeutics

13.16.1 Innate Immunotherapeutics Company Information

13.16.2 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Offered

13.16.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.16.4 Innate Immunotherapeutics Main Business Overview

13.16.5 Innate Immunotherapeutics Latest Developments

14 Research Findings and Conclusion

Table 1. Multiple Sclerosis (MS) Drugs Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)

Table 2. Multiple Sclerosis (MS) Drugs Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)

Table 3. Major Players of Copaxone (Glatiramer Acetate, Copolymer 1)

Table 4. Major Players of Novantrone (Mitoxantrone)

Table 5. Major Players of Gilenya (Fingolimod, Fty720)

Table 6. Major Players of Aubagio (Teriflunomide)

Table 7. Major Players of Tecfidera (Dimethyl Fumarate)

Table 8. Major Players of Firategrast (Sb683699, T-0047)

Table 9. Major Players of Siponimod (Baf312)

Table 10. Major Players of Others

Table 11. Global Multiple Sclerosis (MS) Drugs Sales by Type (2017-2022) & (K Pcs)

Table 12. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2017-2022)

Table 13. Global Multiple Sclerosis (MS) Drugs Revenue by Type (2017-2022) & ($ million)

Table 14. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2017-2022)

Table 15. Global Multiple Sclerosis (MS) Drugs Sale Price by Type (2017-2022) & (USD/Pcs)

Table 16. Global Multiple Sclerosis (MS) Drugs Sales by Application (2017-2022) & (K Pcs)

Table 17. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2017-2022)

Table 18. Global Multiple Sclerosis (MS) Drugs Revenue by Application (2017-2022)

Table 19. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2017-2022)

Table 20. Global Multiple Sclerosis (MS) Drugs Sale Price by Application (2017-2022) & (USD/Pcs)

Table 21. Global Multiple Sclerosis (MS) Drugs Sales by Company (2020-2022) & (K Pcs)

Table 22. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Company (2020-2022)

Table 23. Global Multiple Sclerosis (MS) Drugs Revenue by Company (2020-2022) ($ Millions)

Table 24. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Company (2020-2022)

Table 25. Global Multiple Sclerosis (MS) Drugs Sale Price by Company (2020-2022) & (USD/Pcs)

Table 26. Key Manufacturers Multiple Sclerosis (MS) Drugs Producing Area Distribution and Sales Area

Table 27. Players Multiple Sclerosis (MS) Drugs Products Offered

Table 28. Multiple Sclerosis (MS) Drugs Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 29. New Products and Potential Entrants

Table 30. Mergers & Acquisitions, Expansion

Table 31. Global Multiple Sclerosis (MS) Drugs Sales by Geographic Region (2017-2022) & (K Pcs)

Table 32. Global Multiple Sclerosis (MS) Drugs Sales Market Share Geographic Region (2017-2022)

Table 33. Global Multiple Sclerosis (MS) Drugs Revenue by Geographic Region (2017-2022) & ($ millions)

Table 34. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Geographic Region (2017-2022)

Table 35. Global Multiple Sclerosis (MS) Drugs Sales by Country/Region (2017-2022) & (K Pcs)

Table 36. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Country/Region (2017-2022)

Table 37. Global Multiple Sclerosis (MS) Drugs Revenue by Country/Region (2017-2022) & ($ millions)

Table 38. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Country/Region (2017-2022)

Table 39. Americas Multiple Sclerosis (MS) Drugs Sales by Country (2017-2022) & (K Pcs)

Table 40. Americas Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2017-2022)

Table 41. Americas Multiple Sclerosis (MS) Drugs Revenue by Country (2017-2022) & ($ Millions)

Table 42. Americas Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2017-2022)

Table 43. Americas Multiple Sclerosis (MS) Drugs Sales by Type (2017-2022) & (K Pcs)

Table 44. Americas Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2017-2022)

Table 45. Americas Multiple Sclerosis (MS) Drugs Sales by Application (2017-2022) & (K Pcs)

Table 46. Americas Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2017-2022)

Table 47. APAC Multiple Sclerosis (MS) Drugs Sales by Region (2017-2022) & (K Pcs)

Table 48. APAC Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2017-2022)

Table 49. APAC Multiple Sclerosis (MS) Drugs Revenue by Region (2017-2022) & ($ Millions)

Table 50. APAC Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2017-2022)

Table 51. APAC Multiple Sclerosis (MS) Drugs Sales by Type (2017-2022) & (K Pcs)

Table 52. APAC Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2017-2022)

Table 53. APAC Multiple Sclerosis (MS) Drugs Sales by Application (2017-2022) & (K Pcs)

Table 54. APAC Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2017-2022)

Table 55. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2017-2022) & (K Pcs)

Table 56. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2017-2022)

Table 57. Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2017-2022) & ($ Millions)

Table 58. Europe Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2017-2022)

Table 59. Europe Multiple Sclerosis (MS) Drugs Sales by Type (2017-2022) & (K Pcs)

Table 60. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2017-2022)

Table 61. Europe Multiple Sclerosis (MS) Drugs Sales by Application (2017-2022) & (K Pcs)

Table 62. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2017-2022)

Table 63. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Country (2017-2022) & (K Pcs)

Table 64. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2017-2022)

Table 65. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue by Country (2017-2022) & ($ Millions)

Table 66. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2017-2022)

Table 67. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Type (2017-2022) & (K Pcs)

Table 68. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2017-2022)

Table 69. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Application (2017-2022) & (K Pcs)

Table 70. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2017-2022)

Table 71. Key Market Drivers & Growth Opportunities of Multiple Sclerosis (MS) Drugs

Table 72. Key Market Challenges & Risks of Multiple Sclerosis (MS) Drugs

Table 73. Key Industry Trends of Multiple Sclerosis (MS) Drugs

Table 74. Multiple Sclerosis (MS) Drugs Raw Material

Table 75. Key Suppliers of Raw Materials

Table 76. Multiple Sclerosis (MS) Drugs Distributors List

Table 77. Multiple Sclerosis (MS) Drugs Customer List

Table 78. Global Multiple Sclerosis (MS) Drugs Sales Forecast by Region (2023-2028) & (K Pcs)

Table 79. Global Multiple Sclerosis (MS) Drugs Sales Market Forecast by Region

Table 80. Global Multiple Sclerosis (MS) Drugs Revenue Forecast by Region (2023-2028) & ($ millions)

Table 81. Global Multiple Sclerosis (MS) Drugs Revenue Market Share Forecast by Region (2023-2028)

Table 82. Americas Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2023-2028) & (K Pcs)

Table 83. Americas Multiple Sclerosis (MS) Drugs Revenue Forecast by Country (2023-2028) & ($ millions)

Table 84. APAC Multiple Sclerosis (MS) Drugs Sales Forecast by Region (2023-2028) & (K Pcs)

Table 85. APAC Multiple Sclerosis (MS) Drugs Revenue Forecast by Region (2023-2028) & ($ millions)

Table 86. Europe Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2023-2028) & (K Pcs)

Table 87. Europe Multiple Sclerosis (MS) Drugs Revenue Forecast by Country (2023-2028) & ($ millions)

Table 88. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2023-2028) & (K Pcs)

Table 89. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue Forecast by Country (2023-2028) & ($ millions)

Table 90. Global Multiple Sclerosis (MS) Drugs Sales Forecast by Type (2023-2028) & (K Pcs)

Table 91. Global Multiple Sclerosis (MS) Drugs Sales Market Share Forecast by Type (2023-2028)

Table 92. Global Multiple Sclerosis (MS) Drugs Revenue Forecast by Type (2023-2028) & ($ Millions)

Table 93. Global Multiple Sclerosis (MS) Drugs Revenue Market Share Forecast by Type (2023-2028)

Table 94. Global Multiple Sclerosis (MS) Drugs Sales Forecast by Application (2023-2028) & (K Pcs)

Table 95. Global Multiple Sclerosis (MS) Drugs Sales Market Share Forecast by Application (2023-2028)

Table 96. Global Multiple Sclerosis (MS) Drugs Revenue Forecast by Application (2023-2028) & ($ Millions)

Table 97. Global Multiple Sclerosis (MS) Drugs Revenue Market Share Forecast by Application (2023-2028)

Table 98. Bayer AG Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 99. Bayer AG Multiple Sclerosis (MS) Drugs Product Offered

Table 100. Bayer AG Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 101. Bayer AG Main Business

Table 102. Bayer AG Latest Developments

Table 103. Bayhill Therapeutics Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 104. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Offered

Table 105. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 106. Bayhill Therapeutics Main Business

Table 107. Bayhill Therapeutics Latest Developments

Table 108. Biogen Idec Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 109. Biogen Idec Multiple Sclerosis (MS) Drugs Product Offered

Table 110. Biogen Idec Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 111. Biogen Idec Main Business

Table 112. Biogen Idec Latest Developments

Table 113. Cinnagen Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 114. Cinnagen Multiple Sclerosis (MS) Drugs Product Offered

Table 115. Cinnagen Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 116. Cinnagen Main Business

Table 117. Cinnagen Latest Developments

Table 118. Daiichi Sankyo Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 119. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Offered

Table 120. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 121. Daiichi Sankyo Main Business

Table 122. Daiichi Sankyo Latest Developments

Table 123. Eli Lilly Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 124. Eli Lilly Multiple Sclerosis (MS) Drugs Product Offered

Table 125. Eli Lilly Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 126. Eli Lilly Main Business

Table 127. Eli Lilly Latest Developments

Table 128. Fast Forward Llc Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 129. Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Offered

Table 130. Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 131. Fast Forward Llc Main Business

Table 132. Fast Forward Llc Latest Developments

Table 133. Antisense Therapeutics Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 134. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Offered

Table 135. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 136. Antisense Therapeutics Main Business

Table 137. Antisense Therapeutics Latest Developments

Table 138. Apitope Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 139. Apitope Multiple Sclerosis (MS) Drugs Product Offered

Table 140. Apitope Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 141. Apitope Main Business

Table 142. Apitope Latest Developments

Table 143. Five Prime Therapeutics Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 144. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Offered

Table 145. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 146. Five Prime Therapeutics Main Business

Table 147. Five Prime Therapeutics Latest Developments

Table 148. Genmab Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 149. Genmab Multiple Sclerosis (MS) Drugs Product Offered

Table 150. Genmab Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 151. Genmab Main Business

Table 152. Genmab Latest Developments

Table 153. Artielle Immunotherapeutics Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 154. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Offered

Table 155. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 156. Artielle Immunotherapeutics Main Business

Table 157. Artielle Immunotherapeutics Latest Developments

Table 158. Genzyme Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 159. Genzyme Multiple Sclerosis (MS) Drugs Product Offered

Table 160. Genzyme Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 161. Genzyme Main Business

Table 162. Genzyme Latest Developments

Table 163. Glaxosmithkline Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 164. Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Offered

Table 165. Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 166. Glaxosmithkline Main Business

Table 167. Glaxosmithkline Latest Developments

Table 168. Gw Pharmaceuticals Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 169. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Offered

Table 170. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 171. Gw Pharmaceuticals Main Business

Table 172. Gw Pharmaceuticals Latest Developments

Table 173. Innate Immunotherapeutics Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 174. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Offered

Table 175. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 176. Innate Immunotherapeutics Main Business

Table 177. Innate Immunotherapeutics Latest Developments

List of Figures

Figure 1. Picture of Multiple Sclerosis (MS) Drugs

Figure 2. Multiple Sclerosis (MS) Drugs Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Multiple Sclerosis (MS) Drugs Sales Growth Rate 2017-2028 (K Pcs)

Figure 7. Global Multiple Sclerosis (MS) Drugs Revenue Growth Rate 2017-2028 ($ Millions)

Figure 8. Multiple Sclerosis (MS) Drugs Sales by Region (2021 & 2028) & ($ millions)

Figure 9. Product Picture of Copaxone (Glatiramer Acetate, Copolymer 1)

Figure 10. Product Picture of Novantrone (Mitoxantrone)

Figure 11. Product Picture of Gilenya (Fingolimod, Fty720)

Figure 12. Product Picture of Aubagio (Teriflunomide)

Figure 13. Product Picture of Tecfidera (Dimethyl Fumarate)

Figure 14. Product Picture of Firategrast (Sb683699, T-0047)

Figure 15. Product Picture of Siponimod (Baf312)

Figure 16. Product Picture of Others

Figure 17. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type in 2021

Figure 18. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2017-2022)

Figure 19. Multiple Sclerosis (MS) Drugs Consumed in RRMS

Figure 20. Global Multiple Sclerosis (MS) Drugs Market: RRMS (2017-2022) & (K Pcs)

Figure 21. Multiple Sclerosis (MS) Drugs Consumed in SPMS

Figure 22. Global Multiple Sclerosis (MS) Drugs Market: SPMS (2017-2022) & (K Pcs)

Figure 23. Multiple Sclerosis (MS) Drugs Consumed in PPMS

Figure 24. Global Multiple Sclerosis (MS) Drugs Market: PPMS (2017-2022) & (K Pcs)

Figure 25. Multiple Sclerosis (MS) Drugs Consumed in PRMS

Figure 26. Global Multiple Sclerosis (MS) Drugs Market: PRMS (2017-2022) & (K Pcs)

Figure 27. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2017-2022)

Figure 28. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application in 2021

Figure 29. Multiple Sclerosis (MS) Drugs Revenue Market by Company in 2021 ($ Million)

Figure 30. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Company in 2021

Figure 31. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Geographic Region (2017-2022)

Figure 32. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Geographic Region in 2021

Figure 33. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2017-2022)

Figure 34. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Country/Region in 2021

Figure 35. Americas Multiple Sclerosis (MS) Drugs Sales 2017-2022 (K Pcs)

Figure 36. Americas Multiple Sclerosis (MS) Drugs Revenue 2017-2022 ($ Millions)

Figure 37. APAC Multiple Sclerosis (MS) Drugs Sales 2017-2022 (K Pcs)

Figure 38. APAC Multiple Sclerosis (MS) Drugs Revenue 2017-2022 ($ Millions)

Figure 39. Europe Multiple Sclerosis (MS) Drugs Sales 2017-2022 (K Pcs)

Figure 40. Europe Multiple Sclerosis (MS) Drugs Revenue 2017-2022 ($ Millions)

Figure 41. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales 2017-2022 (K Pcs)

Figure 42. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue 2017-2022 ($ Millions)

Figure 43. Americas Multiple Sclerosis (MS) Drugs Sales Market Share by Country in 2021

Figure 44. Americas Multiple Sclerosis (MS) Drugs Revenue Market Share by Country in 2021

Figure 45. United States Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 46. Canada Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 47. Mexico Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 48. Brazil Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 49. APAC Multiple Sclerosis (MS) Drugs Sales Market Share by Region in 2021

Figure 50. APAC Multiple Sclerosis (MS) Drugs Revenue Market Share by Regions in 2021

Figure 51. China Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 52. Japan Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 53. South Korea Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 54. Southeast Asia Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 55. India Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 56. Australia Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 57. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Country in 2021

Figure 58. Europe Multiple Sclerosis (MS) Drugs Revenue Market Share by Country in 2021

Figure 59. Germany Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 60. France Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 61. UK Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 62. Italy Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 63. Russia Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 64. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Country in 2021

Figure 65. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue Market Share by Country in 2021

Figure 66. Egypt Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 67. South Africa Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 68. Israel Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 69. Turkey Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 70. GCC Country Multiple Sclerosis (MS) Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 71. Manufacturing Cost Structure Analysis of Multiple Sclerosis (MS) Drugs in 2021

Figure 72. Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs

Figure 73. Industry Chain Structure of Multiple Sclerosis (MS) Drugs

Figure 74. Channels of Distribution

Figure 75. Distributors Profiles